18th LIPID CLUB AND THERAPEUTIC APHERESIS – 2023 Edition

MIGHTY MEDIC Org.’s Advanced Clinical Major Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention Seminario Clinico Avanzato e formazione continua in Lipidologia Clinica, Disturbi del Metabolismo, Tecniche Terapeutiche Extracorporee e Prevenzione dell’Aterosclerosi – MIGHTY MEDIC Desenzano del Garda, 4-5 maggio 2023 PROGRAMMA

Malattia aterosclerotica: dai bisogni irrisolti ad una nuova opportunità di gestione del paziente ipercolesterolemico

Genova, 21 novembre 2022 Starhotels President L’evento intende creare un momento di condivisione tra specialisti nella gestione pratica del paziente con ipercolesterolemia a 360°, con lo scopo di: Migliorare il trattamento del paziente con l’utilizzo di farmaci innovativi per il trattamento delle dislipidemie; Valutare del paziente con dislipidemie e approccio …

Continue reading

17° LIPIDCLUB AND THERAPEUTIC APHERESIS

Spoleto, 15-16 settembre 2022 MIGHTY MEDIC Org.’s Advanced Clinical Major Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders,Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention Seminario Clinico Avanzato e formazione continua in Lipidologia Clinica, Disturbi del Metabolismo, Tecniche Terapeutiche Extracorporee e Prevenzione dell’Aterosclerosi PROGRAMMA

16° LIPIDCLUB AND THERAPEUTIC APHERESIS

PICTURES OF THE EVENT October 7-8, 2021 – Verona 16th LIPID CLUB AND THERAPEUTIC APHERESIS Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques and Atherosclerosis Prevention Verona, October 7-8, 2021Camera di Commercio, Industria Artigianato e Agricoltura di Verona Corso Porta Nuova, 96 – 37122 Verona VR …

Continue reading

FCS Announcement

We are collecting anonymised information on patients with familial chylomicronaemia syndrome (FCS)/multifactorial chylomicronaemia syndrome (MCS) as a service evaluation & quality improvement project. The project aims to improve understanding of natural history of FCS and to validate the use of FCS scoring algorithm. The project is approved by Manchester University …

Continue reading

E-ISFA 2020 Announcement

3rd Congress of the European Group – International Society for Apheresis (E-ISFA) Dresden, March 19 to 21, 2020 Congress Topics Recent progress in lipoprotein apheresis Homozygous familial hypercholesterolemia Lipoprotein(a) Competition with drugs Plasma exchange Immunoadsorption – indications, results, future perspectives Experience with extracorporeal therapy in children and during pregnancy Apheresis Registries …

Continue reading

LipidClub 2019

14th Lipid Club and Therapeutic Apheresis 2019 Udine, 30-31 Maggio 2019 ADVANCED COURSE ON CLINICAL LIPIDOLOGY, METABOLIC DISORDERS AND THERAPEUTIC APHERESIS PROGRAMMA DEFINITIVO La notizia su PrimaPaginaNews  

Ipercolesterolemia familiare: una “Call to Action” globale per migliorare la diagnosi

La federazione FH Europe, riunita a Parigi per il suo meeting annuale, contribuirà alla revisione delle politiche mondiali sulla patologia in occasione del Congresso Mondiale di Cardiologia, il mese prossimo a Dubai Parigi – Un’altra generazione di pazienti con ipercolesterolemia familiare (FH) non può essere lasciata indifesa, in balia delle malattie cardiache. Secondo …

Continue reading

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.

OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …

Continue reading